AC
JAZZ icon

AlphaCore Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

AlphaCore Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
+1,279
New +$280K 0.01% 913

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

AlphaCore Capital's JAZZ Position: Q2 2026 in Review

AlphaCore Capital opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 1,279 shares worth $308K. The stake represents 0.01% of the portfolio and ranks #913 among its holdings.

641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • AlphaCore Capital held 1,279 shares of Jazz Pharmaceuticals worth $308K as of Q2 2026.
  • Jazz Pharmaceuticals was a new AlphaCore Capital position in Q2 2026.
  • Jazz Pharmaceuticals made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #913 holding.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.